TAVR (Transcatheter Aortic Valve Replacement)
What is this procedure?
Transcatheter Aortic Valve Replacement (TAVR) is for select patients with severe symptomatic aortic stenosis — a narrowing of the aortic valve opening.
TAVR is an FDA approved procedure for the replacement of the aortic heart valve. A catheter is inserted through a large artery in the leg and threaded up to the aortic valve. A valve on the end of the catheter is then inserted into the opening of the valve.
In the early days of the TAVR procedure, it was limited to patients who were considered extremely high-risk surgical patients because of their age, co-morbidities, frailty or severe heart disease. Shipley is proud of the role we have played in the evolution of the TAVR procedure, and our participation in clinical trials that now make TAVR available to any patient who needs aortic valve replacement.
How is it done?
The TAVR valve leaflets are made of bovine (cow) heart tissue, and are stitched inside of an expandable nickel-nitinol scaffold, or stent.
During the TAVR procedure, the new valve is crimped down to the approximate diameter of a pencil and placed on a catheter. A small incision is made in the groin, and the catheter is fed through the femoral artery to the heart, much like an angioplasty (cardiac catheterization) procedure. Once in the heart chamber, the new valve is positioned directly inside the diseased aortic valve, where the catheter sheath is extracted, and the new valve expands in place. The valve will begin to work immediately, functioning like a normal, healthy valve.
The TAVR procedure is performed under conscious sedation, in a hybrid operating room. A cardiothoracic surgeon and an interventional cardiologist work together, utilizing fluoroscopy and echocardiography to guide the valve to the site of the patient's diseased heart valve.
The TAVR procedure generally is performed in much less time than open-heart surgery, approximately an hour and a half. Additionally, open-heart surgery can require a two- to three-month recovery period, compared to the recovery period of only a few days with the transcatheter approach. Many of our TAVR patients go home the day after the procedure.
Any patient diagnosed with severe aortic stenosis can be referred by their cardiologist to Shipley’s structural heart program clinic for TAVR evaluation.
All potential candidates will be assessed and educated by our specially trained team, consisting of a cardiothoracic surgeon, an interventional cardiologist and a Nurse Navigator. Together they will conduct a comprehensive evaluation to determine whether this procedure is an appropriate option for the patient.
If we find that you are a candidate for the TAVR procedure, you will be given specific instructions and scheduled for surgery at HealthPark Medical Center.
While less invasive than open heart surgical aortic valve replacement, TAVR still has the potential for similar adverse effects, including risk of death, stroke, damage to the artery used for replacement of the valve, major bleeding, and other life-threatening and serious events. While the risks are very low, they still exist.
Technology and expertise at Lee Health
Following FDA approval in late 2011, Shipley Center was the first program in Florida to perform the TAVR procedure. Since that time we have performed over 1400 TAVRs.
Lee Health provides the most advanced valve replacement surgeries and treatments using a multidisciplinary approach. Our structural heart program regularly handles the most complex cases in the region with excellent outcomes.
Shipley Cardiothoracic Center
HealthPark Medical Center
9981 S. HealthPark Dr.
Fort Myers, FL 33908
Hours: 8 a.m. to 4:30 p.m. Monday through Friday